Your email has been successfully added to our mailing list.

×
0 0.00800000000000001 0.018 0.018 0.017 0.00999999999999996 0.00999999999999996 0.00999999999999996
Stock impact report

OmniScience and INmune Bio Partner for Alzheimer's Trial [Yahoo! Finance]

INmune Bio Inc. - Common stock (INMB) 
Company Research Source: Yahoo! Finance
The AI will support the live clinical trial and is expected to increase efficiency and the probability of success, both companies said in a statement. “OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” said Angela Holmes, OmniScience's CEO. Contact: Exec Edge Editor@executives-edge.com Show less Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
INMB alerts

from News Quantified
Opt-in for
INMB alerts

from News Quantified